Skip to content
OpenCapital
Get started

Organon OGN NuvaRing — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

Amneal Pharmaceuticals, Inc. logo
AMRXHormonal / allergy — Net revenue
$35.93M+5.1%
BioMarin Pharmaceuticals logo
BMRNNet product revenues — Total revenues
$760.08M+3.5%
Rhythm Pharmaceuticals, Inc. logo
RYTMProduct revenue, net — Total revenues
$60.11M+59.4%
Exelixis logo
EXELNet product revenues — Total revenues
$554.98M+8.1%
BridgeBio Pharma logo
BBIONet product revenue — Revenue
$180.6M+392%
Perimeter Solutions logo
PRMRevenues from products — Net Sales
$122.57M+81.2%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's nuvaring — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's nuvaring — revenue?
Organon (OGN) reported nuvaring — revenue of $24M in Q1 2026.
How has Organon's nuvaring — revenue changed year-over-year?
Organon's nuvaring — revenue increased by 9.1% year-over-year, from $22M to $24M.
What is the long-term trend for Organon's nuvaring — revenue?
Over 4 years (2021 to 2025), Organon's nuvaring — revenue has grown at a -16.7% compound annual growth rate (CAGR), from $191M to $92M.
What does nuvaring — revenue mean?
This metric represents the total gross sales generated from the NuvaRing contraceptive product line within the women's health portfolio. It serves as a key indicator of market demand and product lifecycle performance for this specific hormonal therapy. Tracking these revenues helps investors assess the competitive positioning and revenue contribution of established women's health assets against newer market entrants.